This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (57)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Rheumatology  • Rheumatology, Other  • Diagnosis  • Alert me on articles by topic  Social Bookmarking   What's this?

Keith T. Rott, MD, PhD; Carlos A. Agudelo, MD

JAMA. 2003;289:2857-2860.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

A study¹ of the diagnosis and treatment of gout in England revealed that less than 10% of patients diagnosed as having gout were referred to rheumatologists, making it a disease most often treated by primary care physicians. The rates of gout reported in primary care practices varied enormously, as did treatment of patients diagnosed as having this condition. Despite centuries of study of gout and the availability of effective treatment for most patients, the proper diagnosis and treatment of gout are still problematic.

The classic presentation of gout is an acute inflammatory monarthritis, often in the first metatarsophalangeal joint, in a middle-aged man. However, not all toe pain is gout. Gout can present in other joints, such as the knee. Gout is sometimes misdiagnosed as cellulitis or septic arthritis. In elderly patients, gout can also present as a chronic . . . [Full Text of this Article]

Hyperuricemia

Risk Factors and Incidence

Clinical Features

Classic Gout

Atypical Gout

Diagnosis

Treatment

Nonsteroidal Anti-inflammatory Drugs

Corticosteroids

Colchicine

Xanthine Oxidase Inhibitors

Uricosurics

Future Therapies

Author Affiliations: Division of Rheumatology and Immunology, Emory University School of Medicine (Drs Rott and Agudelo), and Division of Rheumatology, Atlanta Veterans Affairs Medical Center (Dr Agudelo), Atlanta, Ga.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout
Reinders et al.
Ann Rheum Dis 2009;68:892-897.
ABSTRACT | FULL TEXT  

Frequency, Risk, and Cost of Gout-related Episodes Among the Elderly: Does Serum Uric Acid Level Matter?
WU et al.
The Journal of Rheumatology 2009;36:1032-1040.
ABSTRACT | FULL TEXT  

Serum Uric Acid Is Associated with Carotid Plaques: The National Heart, Lung, and Blood Institute Family Heart Study
NEOGI et al.
The Journal of Rheumatology 2009;36:378-384.
ABSTRACT | FULL TEXT  

Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol
Reinders et al.
Ann Rheum Dis 2009;68:51-56.
ABSTRACT | FULL TEXT  

Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans
Singh and Strand
Ann Rheum Dis 2008;67:1310-1316.
ABSTRACT | FULL TEXT  

Morin (3,5,7,2',4'-Pentahydroxyflavone) Exhibits Potent Inhibitory Actions on Urate Transport by the Human Urate Anion Transporter (hURAT1) Expressed in Human Embryonic Kidney Cells
Yu et al.
Drug Metab. Dispos. 2007;35:981-986.
ABSTRACT | FULL TEXT  

Sex differences in gout epidemiology: evaluation and treatment
Harrold et al.
Ann Rheum Dis 2006;65:1368-1372.
ABSTRACT | FULL TEXT  

Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol.
Pacher et al.
Pharmacol. Rev. 2006;58:87-114.
ABSTRACT | FULL TEXT  

The Dual Actions of Morin (3,5,7,2',4'-Pentahydroxyflavone) as a Hypouricemic Agent: Uricosuric Effect and Xanthine Oxidase Inhibitory Activity
Yu et al.
J. Pharmacol. Exp. Ther. 2006;316:169-175.
ABSTRACT | FULL TEXT  

Superficial collections of fluid tophaceous material as clinical presentation of anorexia nervosa
Garcia-Porrua et al.
Ann Rheum Dis 2005;64:1658-1659.
FULL TEXT  

Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites
Van Aubel et al.
Am. J. Physiol. Renal Physiol. 2005;288:F327-F333.
ABSTRACT | FULL TEXT  

Managing Joint Pain in Primary Care
Palmer and Toombs
J Am Board Fam Med 2004;17:S32-S42.
ABSTRACT | FULL TEXT  

Gout in primary care
DTB 2004;42:37-40.
ABSTRACT | FULL TEXT